In Brief: @fda.gov approves $RVMD’s #Rasonque, a first-in-class RAS inhibitor targeting the most common form of pancreatic cancer. An early-stage trial shows that the drug also has promise in lung cancer www.nature.com/articles/s41...
rdcu.be/hJwr1gqQSW3a